192725-50-1

Basic information

• Product Name: (2S)-(1-Tetrahydropyramid-2-one)-3-methylbutanoic acid
• Synonyms: 2S-(1-TETRAHYDRO-PYRIMID-2-ONLY)-3-METHYL BUTANOIC ACID 99+%;(2S)-(1-Tetrahydropyramid-2-one)-3-methylbutanoic acid-3-methylbutanoic acid;(2S)-(1-Tetrahydropy;2S)-(1-TetrahydropyraMid-2-one)-3-Methylbutanoic a;(S)-3-Methyl-2-(2-oxotetrahydropyriMidin-1(2H)-yl)butanoic acid;(2s)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2h)-yl)butanoic acid;(2S)-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRIC ACID;(2S)-Tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid
• CAS NO: 192725-50-1
• Molecular Formula: C₉H₁₆N₂O₃
• Molecular Weight: 200.23
• EINECS: 1592732-453-0
• Product Categories: Amino Acids & Derivatives;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 192725-50-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 440.793 °C at 760 mmHg
• Flash Point: 220.384 °C
• Appearance: /
• Density: 1.176
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.501
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.39±0.10(Predicted)
• CAS DataBase Reference: (2S)-(1-Tetrahydropyramid-2-one)-3-methylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-(1-Tetrahydropyramid-2-one)-3-methylbutanoic acid(192725-50-1)
• EPA Substance Registry System: (2S)-(1-Tetrahydropyramid-2-one)-3-methylbutanoic acid(192725-50-1)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 192725-50-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 192725-50-1 differently. You can refer to the following data:
1. Lopinavir (L469480) intermediate.
2. Anti-HIV drugs
3. Lopinavir (L469480)

InChI:InChI=1/C9H16N2O3/c1-6(2)7(8(12)13)11-5-3-4-10-9(11)14/h6-7H,3-5H2,1-2H3,(H,10,14)(H,12,13)

Upstream product

• 72-18-4 L-valine 
• 126147-70-4 (2S)-3-Methyl-2-(phenoxycarbonyl)aminobutyric acid 
• 51078-49-0 N-(2-cyanoethyl)-L-valine 
• 192726-03-7 (S)-(-)-N-carboxymethyl-N(β)cyanoethyl valine 
• 6276-54-6 3-chloropropylamine hydrochloride 
• 1026752-79-3 N-(3-aminopropyl)-N-(methoxycarbonyl)-L-valine 
• 192725-84-1 (S)-2-(3-Amino-propylamino)-3-methyl-butyric acid methyl ester 
• 192725-85-2 (S)-3-Methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyric acid methyl ester 
• 14753-26-5 3-chloropropan-1-amine 

Downstream Products

• 192726-06-0 (2S,3S,5S)-2-amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane (S)-pyroglutamic acid salt 
• 192725-17-0 lopinavir 
• 192726-04-8 (2S,3S,5S)-2-N,N-dibenzylamino-3-hydroxy-5-(2S-(2-oxotetrahydropyrimidin-2-yl)-3-methylbutanoyl)amino-1,6-diphenylhexane 
• 402712-50-9 N-(2S-(2-oxotetrahydropyrimidin-1-yl)-3-methylbutanoyl)imidazole 
• 192726-05-9 (2S,3S,5S)-2-amino-3-hydroxy-5-(2S-(2-oxotetrahydropyrimidin-2-yl)-3-methylbutanoyl)amino-1,6-diphenylhexane 
• 192800-77-4 2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl chloride 

Relevant articles and documents

Synthesis and characterization of novel analogues of lopinavir

The present work describes the identification, origin, synthesis, characterization and control of four novel analogues of lopinavir viz. leucine analogue of lopinavir, isoleucine analogue of lopinavir, methyl analogue of lopinavir and dihydroxy analogue of lopinavir.

PROCESSES FOR THE PREPARATION OF LOPINAVIR AND ITS INTERMEDIATE - (S)-TETRAHYDRO-ALPHA-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETIC ACID

The invention relates to processes for the preparation of (S)-tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid or a salt thereof, and to use of this compound as intermediate for the preparation of compounds with antiviral activity. The invention also relates to a process for the preparation of lopinavir, and pharmaceutical compositions that include the lopinavir.

PROCESS FOR PREPARING (S)-TETRAHYDRO-A-(1-METHYLETHYL)-2-OXO-1(2H)- PYRIMIDINEACETIC ACID

A process for preparing (S)-tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid, an intermediate that is useful in the synthesis of HIV protease inhibitors such as, for example, those described in US-5 914 332, is described.The process under consideration comprises the following steps:- L-valine is reacted with acrylonitrile;- the N-(2-cyanoethyl)-L-valine thus obtained is isolated and then reacted with an alkyl chloroformate;- the N-(2-cyanoethyl)-N-(alkoxycarbonyl)-L-valine thus obtained is hydro-genated in the presence of a hydrogenation catalyst, preferably rhodium;- the N-(3-aminopropyl)-N-(methoxycarbonyl)-L-valine thus obtained is cyclized to give the desired compound.